Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 11/20 | 0.41 |
| ▸ | JAK2 | O60674 | 5/20 | 0.41 |
| ▸ | TYK2 | P29597 | 4/20 | 0.41 |
| ▸ | JAK3 | P52333 | 4/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385326 | 0.80 | JAK1 (0.67) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL12425879 | 0.78 | JAK1 (0.47) | JAK1JAK2TYK2JAK3DRD2 | |
| SCHEMBL12424561 | 0.70 | JAK1 (0.47) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL12424336 | 0.70 | JAK1 (0.53) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL12424369 | 0.70 | JAK1 (0.53) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL12424562 | 0.70 | JAK1 (0.48) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL12424357 | 0.68 | JAK1 (0.40) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL12424520 | 0.67 | JAK1 (0.52) | JAK1ALDH1A1HPGD | |
| SCHEMBL12424314 | 0.67 | ACHE (0.47) | HPGDACKR3DRD2 | |
| SCHEMBL12425820 | 0.67 | JAK1 (0.37) | JAK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | JAK1 434/4885JAK2 122/4885TYK2 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.